Kenvue Joins Digital Gut Health Revolution With UK Imodium App
Kenvue’s new Gut2Know app “empowers diarrhea sufferers to boost their gut knowledge and track and identify triggers for their symptoms, such as stress or diet,” the company says. With the launch, Kenvue joins other major players like Bayer and Sanofi who have recently invested in digital digestive health.
You may also be interested in...
The J&J spinout and Neutrogena and Aveeno owner says the challenge facing its Skin Health and Beauty business is not about brand equity or online performance as much as in-store in the US, where it has underperformed. CEO Thibaut Mongon outlined planned investments, expected to drive growth acceleration in Kenvue’s fiscal 2024 second half, at the CAGNY 2024 conference.
A multimillion-dollar partnership will bring together Bayer Consumer Health's digestive health brand equity with Mahana's cutting edge digital therapeutic technology for treating irritable bowel syndrome.
Like other big global OTC players, Bayer Consumer Health is stepping up its investment in digital self-care. In the first part of an exclusive interview, HBW Insight catches up with the company's head of R&D and chief scientific officer David Evendon-Challis to dig deeper into the rationale for setting up a new 'prescision health' business unit, including why a holistic and personalized approach to digital self-care increases trust in long-loved and science-backed brands.